Le‐Qun Li
0000-0002-4143-2921
Publication & Citation Trends
Publications
0 total
Correction: The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection
Cited by 0
Semantic Scholar
Tertiary lymphoid structures in hepatocellular carcinoma: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.
Cited by 9
Semantic Scholar
The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection
Cited by 3
Semantic Scholar
Treatment duration of adjuvant immune checkpoint inhibitor in hepatocellular carcinoma after curative resection: A prospective cohort study.
Cited by 0
Semantic Scholar
Adjuvant Therapy for Hepatocellular Carcinoma After Curative Treatment: Several Unanswered Questions OA
Cited by 8
Semantic Scholar
Adjuvant immune checkpoint inhibitors and association with recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): A prospective cohort study.
Cited by 0
Semantic Scholar
Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study
Cited by 28
Semantic Scholar
Research Topics
Hepatocellular Carcinoma Treatment and Prognosis
(139)
Cholangiocarcinoma and Gallbladder Cancer Studies
(55)
Liver Disease Diagnosis and Treatment
(52)
Cancer, Lipids, and Metabolism
(27)
Cancer Mechanisms and Therapy
(24)
Affiliations
Ministry of Education of the People's Republic of China
Guangxi Medical University
Air Liquide (United Kingdom)
Fudan University
First People’s Hospital of Jingmen